BRO vs RNA · P/E 30, rev $3.58B vs rev $22.6M
Brown & Brown Inc (BRO) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Brown & Brown Inc (BRO) is a insurance brokers company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported BRO revenue for 2026-06-30 was $3.58B. Net income was $714.0M. Revenue was up 88.2% from 2026-03-31 to 2026-06-30. BRO currently screens at market cap $35.56B and trailing P/E 30.0.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
BRO currently screens at market cap $35.56B and trailing P/E 30.0. RNA currently screens at market cap $217.5M.
Not investment advice. Open the BRO and RNA stock pages for the full models.
Not investment advice.